(A) Network map of the top ten anti-AD core targets and the top 30 KEGG pathways. The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 core pathways with DC values (ranked by DC>  average value of (4.933)). حسب Shakeel Ahmad Khan (13202394)

"…The color of the pathway nodes changed from pink to light pink as the DC value decreased. (B) 19 core pathways with DC values (ranked by DC>  average value of (4.933)).…"

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Primary and secondary efficacy end points (intention-to-treat population). حسب Benjamin R. Lewis (22279166)

الموضوعات:

Demographic and clinical characteristics of participants at baseline. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Study flow chart. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study CONSORT diagram. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Changes in baseline T-cell exhaustion, monocyte activation and platelet activation markers through week 12 and week 24 according to the linear regression model. a. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Change in Demoralization Scale (DSII) by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Participants with virologic suppression or failure at week 24. حسب Tosi M. Mwakyandile (16408705)

الموضوعات:

Changes in baseline T-cell activation markers through week 12 and week 24 according to the linear regression model. a. حسب Tosi M. Mwakyandile (16408705)

الموضوعات: